CervoMed Inc. Files 8-K on Financials
Ticker: CRVO · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1053691
| Field | Detail |
|---|---|
| Company | Cervomed Inc. (CRVO) |
| Form Type | 8-K |
| Filed Date | Nov 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
CervoMed dropped its 8-K financials today, check it out.
AI Summary
CervoMed Inc. filed an 8-K on November 10, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company, formerly known as Diffusion Pharmaceuticals Inc., is incorporated in Delaware and headquartered in Boston, MA.
Why It Matters
This 8-K filing provides crucial updates on CervoMed Inc.'s financial performance and condition, which is essential for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- CervoMed Inc. (company) — Registrant
- Diffusion Pharmaceuticals Inc. (company) — Former company name
- 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (location) — Principal executive offices address
- November 10, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on CervoMed Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was this 8-K filed?
This 8-K was filed on November 10, 2025.
What was CervoMed Inc. formerly known as?
CervoMed Inc. was formerly known as Diffusion Pharmaceuticals Inc.
Where is CervoMed Inc. headquartered?
CervoMed Inc. is headquartered at 20 Park Plaza, Suite 424, Boston, Massachusetts 02116.
What is CervoMed Inc.'s state of incorporation?
CervoMed Inc. is incorporated in Delaware.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-11-10 16:05:32
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value CRVO NASDAQ Capital Marke
Filing Documents
- crvo20251110_8k.htm (8-K) — 29KB
- ex_885764.htm (EX-99.1) — 119KB
- cm01.jpg (GRAPHIC) — 6KB
- 0001437749-25-034095.txt ( ) — 296KB
- crvo-20251110.xsd (EX-101.SCH) — 3KB
- crvo-20251110_def.xml (EX-101.DEF) — 11KB
- crvo-20251110_lab.xml (EX-101.LAB) — 15KB
- crvo-20251110_pre.xml (EX-101.PRE) — 11KB
- crvo20251110_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On November 10, 2025, CervoMed Inc. issued a press release announcing financial results as of and for the quarter ended September 30, 2025. A copy of that press release is attached hereto as Exhibit99.1 and incorporated herein by reference. The information included in or incorporated by reference into this Item 2.02 (including Exhibit99.1) is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued November 10, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 10, 2025 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel